secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001104659-23-086393
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure Q2 net loss $68.5M; cash $628.6M; AMT-130 shows preservation of function
--------------------------------------------------------------------------------

- Revenue $2.4M (up from $0.5M YoY); net loss $1.44/share vs $0.84 loss YoY.
- Cash $628.6M (excl. $100M milestone from HEMGENIX 1st US sale received July 2023).
- AMT-130 interim data: preserved clinical function vs natural history; both doses well-tolerated.
- Sale of HEMGENIX royalty for up to $400M; $375M upfront received.
- Appointed Walid Abi-Saab, M.D. as CMO and Jeannette Potts as CLO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923086393/0001104659-23-086393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923086393/tm2322500d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-086393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer